Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophag...
a study on Gastric Adenocarcinoma Stomach Cancer Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Cancer Esophageal Cancer HER2
- for people ages 18 years and up (full criteria)
- at Santa Monica, California and other locations
- study startedestimated completion
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, HER2+, HER2-positive, GEA, GEC, GEJ, Seattle Genetics, Adenocarcinoma, Esophageal Neoplasms, Paclitaxel, Trastuzumab, Ramucirumab, Tucatinib
- accepting new patients
- Start Date
- Completion Date
- Seagen Inc.
- Sign up for this study
- Phase 2/3 research study
- Study Type
- About 17 people participating
- Last Updated